Related Experiment Video

Updated: Jul 17, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited

Vanessa C Gray-Schopfer1, Maria Karasarides, Robert Hayward

  • 1Signal Transduction Team, Cancer Research UK Centre of Cell and Molecular Biology, The Institute of Cancer Research, 237 Fulham Road, London, United Kingdom.

Cancer Research
|January 11, 2007
PubMed

Insights

Tumor necrosis factor-alpha (TNF-alpha) prevents apoptosis in melanoma cells treated with BRAF inhibitors by activating nuclear factor-kappaB (NF-kappaB). This interaction suggests new therapeutic strategies combining BRAF and TNF-alpha/NF-kappaB targeting.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • BRAF mutations drive melanoma proliferation and survival via the RAS/RAF/MEK/ERK pathway.
  • BRAF inhibition is a validated therapeutic strategy, inducing apoptosis in melanoma cells.
  • Understanding resistance mechanisms to BRAF inhibitors is crucial for effective melanoma treatment.

Purpose of the Study:

  • To investigate the effect of tumor necrosis factor-alpha (TNF-alpha) on apoptosis induced by BRAF inhibition in melanoma.
  • To elucidate the specific molecular interactions and signaling pathways involved in TNF-alpha-mediated survival.
  • To explore novel therapeutic combinations for melanoma treatment targeting BRAF and TNF-alpha/NF-kappaB pathways.

Main Methods:

  • Treatment of melanoma cells with BRAF inhibitors and TNF-alpha.
  • Assessment of cell death (apoptosis) and cell cycle re-entry.
  • Evaluation of TNF-alpha's specificity in preventing apoptosis compared to other cytotoxic agents and cytokines.
  • Analysis of nuclear factor-kappaB (NF-kappaB) activation in response to TNF-alpha.

Main Results:

  • TNF-alpha prevented apoptosis induced by BRAF inhibition in melanoma cells, allowing cell cycle re-entry.
  • This survival effect was specific to TNF-alpha, as other agents (cisplatin, nitrogen mustard, thapsigargin) and cytokines (Fas ligand, TRAIL, IL-1, IL-6) did not prevent BRAF inhibitor-induced cell death.
  • TNF-alpha strongly induced nuclear factor-kappaB (NF-kappaB) transcription factor activity, which was essential for the observed survival mechanism.

Conclusions:

  • TNF-alpha confers resistance to BRAF inhibition in melanoma cells through an NF-kappaB-dependent mechanism.
  • The specific interaction between TNF-alpha and BRAF signaling presents a novel therapeutic vulnerability.
  • Combining BRAF/MEK pathway inhibitors with agents targeting TNF-alpha and/or NF-kappaB signaling may offer new treatment opportunities for melanoma.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...